DOAC and carbamazepine — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Reduced apixaban exposure and thrombosis risk
Carbamazepine is an enzyme inducer and can reduce DOAC exposure, increasing thromboembolic risk. This makes reduced apixaban exposure and thrombosis risk the single best answer in this scenario. The other options would either miss the key safety issue, delay appropriate review, or fail to meet the relevant clinical or professional requirement.
Reference: BNF interactions